Comparative evaluation of intranasal and subcutaneous route of immunization for development of mucosal vaccine against experimental tuberculosis

FEMS Immunology and Medical Microbiology

Volumn 45, Issue 1, 2005, Pages 87-93

  Giri, Pramod K ^a   Sable, Suraj B ^a   Verma, Indu ^a   Khuller, Gopal K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Colony forming unit; Culture filtrate proteins; Dimethyldioctadecylammonium bromide; Intranasal; Mycobacterium tuberculosis; Subcutaneous

Indexed keywords

BCG VACCINE; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; GAMMA INTERFERON; IMMUNOGLOBULIN A; INTERLEUKIN 12; INTERLEUKIN 4;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; BACTERIUM CULTURE; BCG VACCINATION; CERVICAL LYMPH NODE; CONTROLLED STUDY; IMMUNOREACTIVITY; LYMPH NODE; LYMPHOCYTE PROLIFERATION; MOUSE; MUCOSAL IMMUNITY; MYCOBACTERIUM; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYSTEM; SPLEEN; TUBERCULOSIS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; CYTOKINES; DISEASE MODELS, ANIMAL; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; INJECTIONS, SUBCUTANEOUS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; QUATERNARY AMMONIUM COMPOUNDS; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY; VACCINATION;

EID: 20544445599     PISSN: 09288244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.femsim.2005.02.009     Document Type: Article

References (25)

1. P.E.M. Fine Variation in protection by BCG: implications of and for heterologous immunity Lancet 346 1995 1339 1345
2. S.H.E. Kaufmann Is the development of a new tuberculosis vaccine possible? Nat. Med. 6 2000 955 960
3. M. Isaka, Y. Yasuda, S. Kozuka, T. Taniguchi, K. Matano, J. Meayama, T. Komiya, and K. Tochikubo Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant Vaccine 18 1999 743 751
4. S.S. Davis Nasal vaccines Adv. Drug. Deliv. Rev. 51 2001 21 42
5. J.M. Kyd, A.R. Foxwell, and A.W. Cripps Mucosal immunity in the lung and upper airway Vaccine 19 2001 2527 2533
6. Y. Kurono, M. Yamamoto, K. Fujihashi, S. Kodama, and G. Mogi Nasal immunization induces Haemophilus influenzae-specific Th1 and Th2 responses with mucosal IgA and systemic IgG antibodies for protective immunity Vaccine 19 1999 122 132
7. L. Hann, W.R. Verweij, M. Holtrop, R. Brands, G.J. van Scharrenburg, and A.M. Palache Nasal or intramuscular immunization of mice with influenzae subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA or IgG mediated protective mucosal immunity Vaccine 19 2001 2898 2907
8. M. Saito, S. Otake, M. Ohmura, M. Hirsawa, K. Takada, and J. Mega Protective immunity to Streptococcus mutans induced by nasal vaccination with surface protein antigen and mutant cholera toxin adjuvant J. Infect. Dis. 183 2001 823 826
9. G. Falera-Diaz, S. Challacombe, D. Banerjee, G. Douce, A. Boyd, and J. Ivanyi Intranasal vaccination of mice against infection with Mycobacterium tuberculosis Vaccine 18 2000 3223 3229
10. C. Klinguer, A. Beck, P. De-Lys, M.C. Bussat, A. Blaecke, F. Deroult, J.Y. Bonnefoy, T.N. Nguygen, N. Corvaia, and D. Velin Lipophilic quaternary ammonium salt act as a mucosal adjuvant when co-administered by the nasal route with vaccine antigens Vaccine 19 2001 4236 4244
11. J.P. Stanfield, D. Gall, and P.M. Bracken Single-dose antenatal tetanus immunization Lancet. ii 1973 215 219
12. D. Subrahmanyam Studies on the poly glycerophosphatides of Mycobacterium tuberculosis Can. J. Biochem. 42 1964 1192 1201
13. L. Brandt, M. Elhay, I. Rosenkrands, E.B. Lindbald, and P. Andersen ESAT-6 subunit vaccination against Mycobacterium tuberculosis Infect. Immun. 68 2000 791 795
14. M. Pizza, M.M. Giuliani, M.R. Fontana, E. Monaci, G. Douce, and G. Daugan Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants Vaccine 19 2000 2534 2541
15. L.A.T. Hilgers, and H. Snippe DDA as an immunological adjuvant Res. Immunol. 143 1992 494 503
16. P. Andersen Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins Infect. Immun. 62 1994 2536 2544
17. E.B. Lindblad, M.J. Elhay, R. Silva, R. Appelberg, and P. Andersen Adjuvant modulation of immune responses to tuberculosis sub-unit vaccines Infect. Immun. 65 1997 623 629
18. M.J. Hsieh, A.P. Junqueira-Kipnis, A. Hoeffer, O.C Turner, and I.M. Orme Incorporation of CpG oligodeoxynucleotide fails to enhance the protective efficacy of a subunit vaccine against Mycobacterium tuberculosis Vaccine 22 2004 655 659
19. P.L. Ogra, H. Faden, and R.C. Welliver Vaccination strategies for mucosal immune responses Clin. Microbiol. Rev. 14 2001 430 445
20. S.G. Rhodes, and S.P. Graham Is 'timing' important for cytokine polarization Trends Immunol. 169 2002 366 374
21. H.M. Surcel, M. Troye-Blomberg, S. Paulie, G. Andersson, C. Moreno, and G. Pasvol Th1/Th2 profile in tuberculosis based on the proliferation and cytokine response on blood lymphocyte to mycobacterial antigens Immunology. 81 1994 171 176
22. H. Kiyono, J. Bienenstock, J.R. McGhee, and P.B. Ernst The mucosal immune system: features of inductive and effector sites to consider in mucosal immunization and vaccine development Reg. Immunol. 4 1992 54 62
23. A. Glatman-Freedman, and A. Casadevall Serum therapy for tuberculosis revisited reappraisal of the role of antibody-mediated immunity against tuberculosis Clin Microbiol. Rev. 11 1998 514 532
24. A. Williams, R. Reljic, I. Naylor, S.O. Clark, G. Falero Diaz, M. Singh, and S. Challacombe Passive protection with immunoglobulin A antibodies against tuberculosis early infection of the lungs Immunology 111 2004 328 333
25. A. Rodriguez, M. Troye-Blomberg, K. Lindroth, J. Ivanyi, M. Singh, and C. Fernande z B- and T-cell responses to the Mycobacterium surface antigen PstS-1 in the respiratory tract and adjacent tissues Role of adjuvants and routes of immunization Vaccine 21 2003 458 467